scispace - formally typeset
H

Hsing Jien Kung

Researcher at Taipei Medical University

Publications -  359
Citations -  33887

Hsing Jien Kung is an academic researcher from Taipei Medical University. The author has contributed to research in topics: Prostate cancer & Tyrosine kinase. The author has an hindex of 85, co-authored 349 publications receiving 30686 citations. Previous affiliations of Hsing Jien Kung include California Institute of Technology & University of Southern California.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells.

TL;DR: Differential expression of miR-125b is found in androgen-dependent and independent CaP cells, as well as in benign and malignant prostate tissues, and transfection of synthetic miR -125b stimulated androgens-independent growth ofCaP cells and down-regulated the expression of Bak1.
Journal ArticleDOI

Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.

TL;DR: This review summarizes the evolution, early success, current status, challenges, and opportunities for clinical application of genotyping and genomic tests in therapeutic decision making for NSCLC.